Mumbai : Siro Clinpharm, one of India’s largest Clinical research organizations, has appointed Pitchfork Partners as its strategic communication partner.
Clinical research is an indispensable part of the drug development process ensuring the safety and efficacy of any new drug. Today, clinical trials are the mainstay for bringing newer and better drugs to market. According to industry estimates, there is a significant rise in clinical trial approvals. Regulatory changes have brought clinical research in India on track with the market expected to grow at a CAGR of approximately 12%.
Incorporated in 1996, SIRO Clinpharm supports trials from Phase II to Phase IV and beyond post-launch of products. It offers a range of services, from clinical operations to data services, data analytics and medical writing in compliance with international standards. SIRO has an unmatched track record, conducting more than 200 clinical projects across various geographies. SIRO has been named ‘Indian Clinical Research Organisation of the Year’ for two consecutive years by Frost and Sullivan. SIRO was also recognised by CMO Asia as the ‘Best Clinical Research Organisation in India’.
Karan Daftary, Director, Siro Clinpharm, said: “Pitchfork Partners shares our beliefs and values, and we are delighted to partner with them. We started this business two decades ago and are currently one of the leading clinical trials companies in India. We see a huge opportunity for sustained growth and Pitchfork has the credentials to help us.”
Jaideep Shergill, Co-Founder, Pitchfork Partners, said: “We are excited to partner with Siro Clinpharm. The company is considered a pioneer and we are committed to helping it achieve its business goals through strategic and insights-driven communication. Siro has shared with us an ambitious roadmap and we are looking forward to partnering it in achieving its goals.”
